Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 18:23:100495.
doi: 10.1016/j.lrr.2024.100495. eCollection 2025.

Targeting menin for precision therapy in high-risk acute myeloid leukemia

Abdur Jamil  1 , Zaheer Qureshi  2 , Zain Mary El-Amir  3 , Gillian Kupakuwana-Suk  4 , Hamzah Akram  5 , Mohsin Ahmad  6 , Eric Huselton  7
Affiliations
Review

Targeting menin for precision therapy in high-risk acute myeloid leukemia

Abdur Jamil et al. Leuk Res Rep. .

Abstract

Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways.

Summary: The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.

Keywords: Acute myeloid leukemia; KMT2A; Menin inhibition therapy; Revumenib.

PubMed Disclaimer

Conflict of interest statement

All authors have no competing interest to declare.

Similar articles

See all similar articles

Cited by

References

    1. Bain B.J., Béné M.C. Morphological and immunophenotypic clues to the WHO categories of acute myeloid leukaemia. Acta Haematol. 2019;141:232–244. doi: 10.1159/000496097. - DOI - PubMed
    1. Naymagon L., Marcellino B., Mascarenhas J. Eosinophilia in acute myeloid leukemia: overlooked and underexamined. Blood Rev. 2019;36:23–31. doi: 10.1016/j.blre.2019.03.007. - DOI - PubMed
    1. Medeiros B.C., Chan S.M., Daver N.G., Jonas B.A., Pollyea D.A. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am. J. Hematol. 2019;94:803–811. doi: 10.1002/ajh.25484. - DOI - PMC - PubMed
    1. Shallis R.M., Wang R., Davidoff A., Ma X., Zeidan A.M. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70–87. doi: 10.1016/j.blre.2019.04.005. - DOI - PubMed
    1. Papaemmanuil E., Gerstung M., Bullinger L., Gaidzik V.I., Paschka P., Roberts N.D., Potter N.E., Heuser M., Thol F., Bolli N., Gundem G., Van Loo P., Martincorena I., Ganly P., Mudie L., McLaren S., O'Meara S., Raine K., Jones D.R., Teague J.W., Butler A.P., Greaves M.F., Ganser A., Döhner K., Schlenk R.F., Döhner H., Campbell P.J. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 2016;374:2209–2221. doi: 10.1056/NEJMoa1516192. - DOI - PMC - PubMed

LinkOut - more resources